Le Lézard
Classified in: Health, Business
Subject: RCN

Rodan + Fields Announces New Path to Growth


Company will expand reach of its dermatology-created products with a modernized approach to its people centered business model

SAN FRANCISCO, July 15, 2024 /PRNewswire/ -- Rodan + Fields ("R+F" or "the Company")?a brand known for delivering proven results in skincare and haircare through science-backed, dermatologist-created products?today announced a simplified business model to unlock growth and reach new customers.

Rodan + Fields to move away from multi-level direct selling model to streamline customer and Consultant experience

Starting September 1, the Company will move away from the multi-level direct selling model to streamline the customer and Consultant experience. This new model, which will be supported by a broader array of marketing and advertising across traditional channels and social media to complement Consultants' advocacy, will better position R+F to meet customers where they are discovering and buying beauty products.

When the new model takes effect on September 1:

"Since day one, our brand has been focused on giving people the proven results they desire in skincare and haircare through science-backed, dermatologist-created products," said Dimitri Haloulos, CEO of R+F. "We are confident these changes will enable us to meaningfully expand the lives we can impact and?importantly?allow us to continue to provide our passionate Consultants with a modern and meaningful earning opportunity."

As part of the evolution of its business model, R+F has also reorganized its corporate structure to support the future needs of the business, which resulted in the elimination of approximately 100 roles. The Company is grateful for the contributions of these individuals and is supporting them with the transition.  

About Rodan + Fields:
Rodan + Fields was launched in 2008 and founded by Stanford-trained dermatologists Dr. Katie Rodan and Dr. Kathy Fields with the mission of delivering proven results in skincare and haircare through science-backed, dermatologist-created products. Rodan + Fields is the #1 Dermatologist Founded Premium Skincare Brand in North America in 2022? and the #1 Premium Skincare Regimen Brand in the U.S. for 5 consecutive years, (2018 ? 2022)+. Rodan + Fields is proud of its track record of providing confidence to millions through regimen-based skincare and award-winning innovation, and global community of passionate brand advocates. Products are available through R+F Independent Consultants or on the Rodan + Fields website at rodanandfields.com.

+ Source Euromonitor International Limited; Beauty and Personal Care 2023 Edition, retail value RSP terms; all channels, Premium Skincare.

? Source Euromonitor International Limited; Beauty and Personal Care 2023 Edition; all channels; Premium Skin Care Regimen includes Sets and Kits; retail value RSP terms.

SOURCE Rodan + Fields


These press releases may also interest you

at 04:05
AuriGen Medical, a medical device company specializing in left atrial appendage occlusion (LAAO) technology, today announced the successful treatment of their first patient in its first-in-human clinical study. The procedure, performed by Dr Matt...

at 04:00
Tennessee Valley Group proudly announces that its President, Jim Cumbee and his client, Greg Edwards, Founder & CEO of Onsight Healthcare, recently appeared on the Harvard Business School podcast, Think Big Buy Small. Co-hosted by Harvard professors...

at 03:30
Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat cancer and...

at 03:05
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide US healthcare provider MaineGeneral Health its enterprise imaging as a fully hosted public cloud service, Sectra One Cloud. The comprehensive solution will...

at 03:00
Clarivate Plc , a leading global provider of transformative intelligence, today announced the success of its annual Citation Laureatestm program, following the accurate forecast of eight Nobel Prize 2024 recipients....

at 02:35
Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in Vienna. The post-hoc analysis from the LIBERTY-CD (Crohn's disease) and LIBERTY-UC...



News published on and distributed by: